Shanghai RAAS Blood Products Co., Ltd.

002252

CNE100000C31

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2026-03-10			5-day change	1st Jan Change
6.240 ^CNY	0.00%		-0.95%	-1.58%

Mar. 10	RAAS Blood Products Gets Plasma Collection License for Fengzhen Tonglu Plasma Collection Station	MT
Feb. 02	Shanghai Raas Announces Profit Distribution Plan to Be Implemented on A Share for the Third Quarter of 2025, Payable on February 10, 2026	CI

Shanghai Raas Co., Ltd. Proposes Cash Dividend for the Third Quarter of 2025

Published on 12/01/2025 at 02:32 pm EST

S&P Capital IQ

SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.

0.00%

Shanghai RAAS Co., Ltd. at the EGM to be held on 15 December 2025, proposed Cash dividend (tax included): CNY 0.15300000 per ten shares, for the third quarter of 2025.

Latest news about Shanghai RAAS Blood Products Co., Ltd.

Mar. 10	RAAS Blood Products Gets Plasma Collection License for Fengzhen Tonglu Plasma Collection Station	MT
Feb. 02	Shanghai Raas Announces Profit Distribution Plan to Be Implemented on A Share for the Third Quarter of 2025, Payable on February 10, 2026	CI
Dec. 01	Shanghai Raas Co., Ltd. Proposes Cash Dividend for the Third Quarter of 2025	CI
Nov. 05	Shanghai RAAS Blood Products Gets Trial Approval for Blood Clotting Disorder	MT
25-10-28	Shanghai Raas Blood Products Co., Ltd. Announces Profit Distribution Proposal for the Third Quarter of 2025	CI
25-10-28	Tranche Update on Shanghai RAAS Blood Products Co., Ltd.'s Equity Buyback Plan announced on January 14, 2025.	CI
25-10-27	Shanghai RAAS Blood Products Co., Ltd.'s Equity Buyback announced on January 14, 2025, has closed with 69,081,952 shares, representing 1.04% for CNY 474.94 million.	CI
25-10-27	Shanghai RAAS Blood Products Q3 net profit down 26.2% Y/Y	RE
25-10-27	Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-10	Tranche Update on Shanghai RAAS Blood Products Co., Ltd.'s Equity Buyback Plan announced on January 14, 2025.	CI
25-08-29	Shanghai RAAS Blood Products H1 net profit down 17.0% Y/Y	RE
25-08-29	Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-09	Shanghai RAAS Gets China Clinical Trial Approval for Blood Clot Drug	MT
25-07-01	Tranche Update on Shanghai RAAS Blood Products Co., Ltd.'s Equity Buyback Plan announced on January 14, 2025.	CI
25-06-19	RAAS Blood Products Completes Full Acquisition of Nanyue Biopharmaceutical	MT

Chart Shanghai RAAS Blood Products Co., Ltd.

Duration

Period

Chart Shanghai RAAS Blood Products Co., Ltd.

002252: Dynamic Chart

Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin). China accounts for 96.6% of net sales.

Employees

3,350

Sector

Pharmaceuticals

Calendar

Mar. 27 - Earnings release - Annual 2025

More about the company